Table 1.
Clinical trials of ATO-based therapy in relapsed/refractory myeloma patients
| Reference | Regimen | Patients | PFS | OS | MR (%) | PR (%) | CR (%) | Comments |
|---|---|---|---|---|---|---|---|---|
| Hussein et al48 | ATO 0.25 mg | 24 | 33 | Object response, ≥25% reduction in serum M-protein, is considered as PR | ||||
| Yan et al45 | ATO 0.14 mg/kg | 21 | 47.6 | 42.9 | ||||
| Abou-Jawde et al27 | ATO 0.25 mg/kg + AA 1 g + dex 40 mg | 20 | 316 days (10.5 months) in all patients 584 days in those with a response | 962 (32 months) days | 20 | 10 | ||
| Baz et al49 | ATO 0.25 mg/kg + AA 1 g + dex 20 mg + thali 100 mg | 16 | 9.4 months | 0 | 31 | 0 | ||
| Berenson et al26 | ATO 0.25 mg/kg + AA 1 g + mel 0.1 mg/kg | 65 | 7 months | 19 months | 22 | 23 | 3 | |
| Berenson et al25 | ATO 0.125/0.25 mg/kg + AA 1 g + bortezomib 0.7/1.0/1.3 mg/m2 | 22 | 5 months | >18 months | 18 | 9 | 0 | OS has not been reached yet with a median follow-up of 13 months |
| Wu et al28 | ATO 0.25 mg/kg + AA 1 g + dex 40/20 mg | 20 | 4 months | 11 months | 30 | 10 | 0 | |
| Dey et al23 | ATO 0.14 mg/kg | 15 | 0 | 40 | 33 | |||
| Qazilbash et al24 | Mel 200 mg/m2 + AA 1 g + arm 1: no ATO, arm 2: ATO 0.15 mg/kg, arm 3: ATO 0.25 mg/kg | 48 | 24 months | 60 | 25 | |||
| Zhang and Bao44 | ATO 0.14 mg/kg + dex 20 mg + thali 100 mg | 29 | 85.7 |
Abbreviations: AA, ascorbic acid; ATO, arsenic trioxide; CR, complete response; dex, dexamethasone; mel, melphalan; MR, minor response; OS, overall survival; PFS, progression-free survival; PR, partial response; thali, thalidomide.